Higher Framingham steatosis index is associated with prevalent breast cancer in women: cross-sectional evidence from NHANES 1999–2018 and an exploratory hospital-based dataset - Scorecard - MDSpire

Higher Framingham steatosis index is associated with prevalent breast cancer in women: cross-sectional evidence from NHANES 1999–2018 and an exploratory hospital-based dataset

  • By

  • Shuling Tang

  • Yong Mo

  • Tiansheng Su

  • Guangxiang Huang

  • Jiachao Lu

  • Jianbin Bi

  • Hui Li

  • Ligen Mo

  • Jun Yan

  • July 8, 2026

  • 0 min

Share

Clinical Scorecard: Association of Elevated Framingham Steatosis Index with Existing Breast Cancer in Women: Insights from NHANES 1999–2018 and a Supplementary Hospital Dataset

At a Glance

CategoryDetail
ConditionBreast Cancer
Key MechanismsAssociation of Framingham Steatosis Index (FSI) with metabolic dysfunction and hepatic steatosis-related phenotypes.
Target PopulationAdult women aged 18 years or older.
Care SettingCross-sectional analysis using NHANES data.

Key Highlights

  • 2.5% of women in NHANES reported a history of breast cancer.
  • Each 1-unit increase in FSI was associated with higher odds of prevalent breast cancer (OR 1.10).
  • Association was attenuated after adjustment for age (OR 1.02).
  • Higher FSI quartiles correlated with greater odds of prevalent breast cancer.
  • FSI should be interpreted as a composite marker of metabolic-hepatic burden.

Guideline-Based Recommendations

Diagnosis

  • Breast cancer status determined through standardized NHANES questionnaire data.

Management

  • FSI should be considered in the context of broader metabolic dysfunction rather than as a direct diagnostic measure.

Monitoring & Follow-up

  • Regular assessment of metabolic components associated with FSI.

Risks

  • Higher FSI may indicate increased risk for prevalent breast cancer.

Patient & Prescribing Data

Women with complete metabolic biomarker data from NHANES.

FSI is a composite index and should be interpreted with caution regarding its implications for breast cancer risk.

Clinical Best Practices

  • Utilize FSI as a non-invasive surrogate marker for hepatic steatosis in assessing breast cancer risk.
  • Consider age and other metabolic factors when interpreting FSI results.

Related Resources & Content

Original Source(s)

Related Content